Company: DMAAR
Filing Date: 2025-01-14
Form Type: POS AM
Source: 0001213900-25-003137
Chunk: 7

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-14
Form: POS AM
Chunk 7
---
 when such separate trading will begin. Once the securities constituting the units begin separate trading, we expect that the ordinary shares and rights will be listed on Nasdaq under the symbols “DMAA” and “DMAAR,” respectively. We are an “emerging growth company” and a “smaller reporting company” under applicable federal securities laws and will be subject to reduced public company reporting requirements. Investing in our securities involves a high degree of risk. See “ Risk Factors ” beginning on page 38 for a discussion of information that should be considered in connection with an investment in our securities. Investors will not be entitled to protections normally afforded to investors in Rule 419 blank check offerings. Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

No offer or invitation, whether directly or indirectly, is being or may be made to the public in the Cayman Islands to subscribe for any of our securities.

|                                           |     | Per Unit |       |     | Total |             |
|:------------------------------------------|:----|:---------|------:|:----|:------|------------:|
| Public offering price                     |     | $        | 10.00 |     | $     | 200,000,000 |
| Underwriting discounts and commissions(1) |     | $        |  0.35 |     | $     |   7,000,000 |
| Proceeds, before expenses, to us          |     | $        |  9.65 |     | $     | 193,000,000 |

____________ (1)$0.05 per unit sold in the base offering, or 0.5% of the gross proceeds of the offering, or $1,000,000 (or up to $1,150,000 if the overallotment option is exercised in full) in the aggregate, is payable upon the closing of this offering. Includes $0.30 per unit, or 3.0% of the gross proceeds of the offering, or $6,000,000 (or up to $6,900,000 if the underwriters’ over -allotmentoption is exercised in full) in the aggregate, of which 25.0% will be adjusted net of redemptions (i.e., for purposes of calculating the deferred underwriting commission net of redemptions, 25